VR Logo

Renalytix plc (RNLX) download report


Healthcare | Diagnostics Services

Renalytix plc (RNLX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases.

IPO Date: 17-Jul-2020

CEO & Exec. Director: Mr. James R. McCullough M.B.A.

CTO & Exec. Director: Mr. Fergus Fleming

Listing: NASDAQ: RNLX

Country: United States

Headquarters: New York, NY

Website: https://renalytix.com

Key Facts

Market cap: $148.40 Mln

Revenue (TTM): $2.42 Mln

Earnings (TTM): $-41.58 Mln

Cash: $46.96 Mln

Total Debt: $0.00 Mln

Insider's Holding: 0.00%

Liquidity: Low

52 Week range: $2.23 - 34.98

Shares outstanding: 37,380,200

Stock Performance

Time Period Renalytix (RNLX) S&P BSE Sensex S&P Small-Cap 600
YTD-83.90-9.18-18.78
1 month-38.90-4.78-8.00
3 months-63.01-9.66-13.65
1 Year-91.700.81-17.19
3 Years--10.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year Renalytix (RNLX) S&P Small-Cap 600 S&P BSE Sensex
2021-0.6325.2721.99